Choosing Your Healthcare Investment: Broad Sector Reach or Focused Pharma Power
Understanding the Core Differences: Broad Exposure vs. Specialized Focus
The Fidelity MSCI Health Care Index ETF (FHLC) offers investors a wide-ranging stake in the entire healthcare industry. In contrast, the VanEck Pharmaceutical ETF (PPH) provides a highly concentrated investment exclusively within the global pharmaceutical sector, targeting major drug manufacturers. The fundamental decision for investors lies in balancing comprehensive industry coverage against a specialized, high-yield pharmaceutical focus.
Comparative Metrics: Expense Ratios, Yields, and Asset Management
A significant distinction between the two funds is their expense ratios; FHLC is considerably more economical with a fee of just 0.08%, compared to PPH's 0.36%. However, PPH offers a more attractive dividend yield, currently providing a 0.7 percentage point advantage over FHLC, which may appeal to income-focused investors. As of August 20, 2026, PPH shares were priced at $115.08 with a 1.9% dividend yield, while FHLC traded at $83.64 with a 1.2% yield. FHLC manages a larger asset base of $3.3 billion, whereas PPH has $1.0 billion in assets under management (AUM).
Investment Performance and Risk Assessment
Over the past five years, PPH has demonstrated superior growth, with a total return of $1,656 from an initial $1,000 investment, compared to FHLC's $1,332. Despite this, PPH experienced a slightly deeper maximum drawdown of -20.3% against FHLC's -17.7% over the same period, indicating a higher level of volatility. Both funds exhibit a beta less than 1 (PPH at 0.46 and FHLC at 0.60), suggesting they are less volatile than the broader S&P 500 index.
Portfolio Composition: Diversification vs. Concentration
FHLC’s portfolio includes 365 holdings, providing broad exposure across the healthcare sector, with major stakes in Eli Lilly & Co (13.3%), Johnson & Johnson (8.8%), and Abbvie Inc (6.5%). Launched in 2013, it primarily invests in US stocks. PPH, established in 2011, is much more concentrated with only 26 holdings, exclusively focusing on pharmaceuticals. Its top holdings include Eli Lilly & Co (19.1%), Merck & Co Inc (7.8%), and Novartis Ag (10.5%). This strategic difference allows FHLC to capture diverse sub-sectors like health insurance, whereas PPH maintains a tight focus on pharmaceutical manufacturing.
Evaluating the Optimal Investment Choice
While both ETFs offer robust exposure to the healthcare domain and allocate a significant portion of their assets to top holdings, key structural differences dictate their investment profiles. PPH leans heavily towards large-cap companies, comprising 90% of its assets, and diversifies globally, with only 64% in U.S. stocks. FHLC, on the other hand, dedicates 66% to large caps, 22% to mid-caps, and 11% to small caps, with nearly 100% of its holdings in U.S. companies. Historically, PPH has outperformed FHLC over the 3-year (14.4% vs. 8.9%) and 5-year (10.2% vs. 5.1%) periods, though FHLC showed stronger 10-year returns (9.9% vs. 8%). Given PPH's recent strong performance and concentrated strategy, it appears to be the more compelling choice for investors seeking a focused pharmaceutical investment.
